PriceTargets.com logo

Augmedix - AUGX Stock Price Target and Predictions

  • Consensus Rating: N/A
  • Consensus Price Target: $6.50
  • Forecasted Upside: 132.97%
  • Number of Analysts: 0
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$2.79 As of 04/25/2024 01:00 AM ET
▼ -0.06 (-2.11%)

This chart shows the closing price for AUGX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Augmedix Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AUGX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AUGX

Analyst Price Target is $6.50
▲ +132.97% Upside Potential
This price target is based on 0 analysts offering 12 month price targets for Augmedix in the last 3 months. The average price target is $6.50, with a high forecast of $6.50 and a low forecast of $6.50. The average price target represents a 132.97% upside from the last price of $2.79.

This chart shows the closing price for AUGX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is N/A

The current consensus among 0 investment analysts is to n/a stock in Augmedix. This N/A consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/2/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/31/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/1/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
7/30/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
10/28/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
1/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/26/2024
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
4/25/2024

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
8/8/2023B. RileyBoost Target$5.50 ➝ $6.50
5/15/2023B. RileyBoost Target$5.00 ➝ $5.50
4/21/2023Maxim GroupBoost TargetBuy$5.00 ➝ $8.00
4/21/2023BenchmarkBoost TargetBuy$5.00 ➝ $6.00
4/20/2023B. RileyBoost TargetBuy$4.00 ➝ $5.00
3/31/2023BenchmarkReiterated RatingBuy$5.00
3/28/2023Maxim GroupBoost TargetBuy$4.00 ➝ $5.00
12/29/2022B. RileyReiterated RatingBuy
8/1/2022B. RileyLower Target$6.50 ➝ $4.50
3/7/2022Lake Street CapitalInitiated CoverageBuy$6.00
1/21/2022Maxim GroupInitiated CoverageBuy$6.00
11/1/2021William BlairInitiated CoverageOutperform
11/1/2021BenchmarkInitiated CoverageBuy$6.00
10/29/2021B. RileyReiterated RatingBuy
6/10/2021B. RileyInitiated CoverageBuy$9.00
(Data available from 4/26/2019 forward)

News Sentiment Rating

0.61 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
9/28/2023
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
10/28/2023
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/27/2023
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/27/2023
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/26/2024
  • 2 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/25/2024
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/26/2024
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
4/25/2024

Current Sentiment

  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Augmedix logo
Augmedix, Inc. provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits. The company enables clinicians to access its applications through mobile devices, such as smartphones. It serves health systems and specialty groups. The company was founded in 2013 and is headquartered in San Francisco, California.
Read More

Today's Range

Now: $2.79
Low: $2.61
High: $2.85

50 Day Range

MA: $3.88
Low: $2.79
High: $4.68

52 Week Range

Now: $2.79
Low: $2.61
High: $6.25

Volume

244,806 shs

Average Volume

366,251 shs

Market Capitalization

$135.98 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Augmedix?

The following Wall Street sell-side analysts have issued stock ratings on Augmedix in the last twelve months: B. Riley.
View the latest analyst ratings for AUGX.

What is the current price target for Augmedix?

1 Wall Street analysts have set twelve-month price targets for Augmedix in the last year. Their average twelve-month price target is $6.50, suggesting a possible upside of 133.0%. B. Riley has the highest price target set, predicting AUGX will reach $6.50 in the next twelve months. B. Riley has the lowest price target set, forecasting a price of $6.50 for Augmedix in the next year.
View the latest price targets for AUGX.

What is the current consensus analyst rating for Augmedix?

Augmedix currently has from Wall Street analysts. The stock has a consensus analyst rating of "N/A."
View the latest ratings for AUGX.

What other companies compete with Augmedix?

Other companies that are similar to Augmedix include Forian, Syros Pharmaceuticals, Molecular Partners, Sagimet Biosciences and DBV Technologies. Learn More about companies similar to Augmedix.

How do I contact Augmedix's investor relations team?

The company's listed phone number is 888-669-4885 and its investor relations email address is [email protected]. The official website for Augmedix is www.augmedix.com. Learn More about contacing Augmedix investor relations.